BackgroundImproved prediction of Parkinson's disease (PD) progression is needed to support clinical decision-making and to accelerate research trials.ObjectivesTo examine whether baseline measures and their 1-year change predict longer-term progression in early PD.MethodsParkinson's Progression Markers Initiative study data were used. Participants had disease duration ≤2 years, abnormal dopamine transporter (DAT) imaging, and were untreated with PD medications. Baseline and 1-year change in clinical, cerebrospinal fluid (CSF), and imaging measures were evaluated as candidate predictors of longer-term (up to 5 years) change in Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score and DAT specific binding ratio...
Background Both patients and physicians may choose to delay initiation of dopamine replacement thera...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
BackgroundImproved prediction of Parkinson's disease (PD) progression is needed to support clinical ...
Background: Improved prediction of Parkinson’s disease (PD) progression is needed to support clinica...
ObjectiveThe objective of this study was to assess longitudinal change in clinical and dopamine tran...
Background: Clinical progression of Parkinson\u27s disease (PD) is highly heterogeneous, and its pre...
BACKGROUND: Identifying a meaningful progression metric for Parkinsons disease (PD) that reflects he...
OBJECTIVES: Developing disease modifying therapies for Parkinson's disease (PD) calls for outcome me...
Currently, no treatments available for Parkinson's disease (PD) can slow PD progression. At the earl...
Objective: The aim of this study is to present a predictive model of Parkinson's disease (PD) global...
This thesis examined the factors correlated with rapid and benign progression of disease in a group ...
ObjectiveTo determine clinical and biological variables that predict time to initiation of symptomat...
Background: Both patients and physicians may choose to delay initiation of dopamine replacement ther...
Parkinson's disease is the second most common neurological disease and affects about 1% of persons o...
Background Both patients and physicians may choose to delay initiation of dopamine replacement thera...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
BackgroundImproved prediction of Parkinson's disease (PD) progression is needed to support clinical ...
Background: Improved prediction of Parkinson’s disease (PD) progression is needed to support clinica...
ObjectiveThe objective of this study was to assess longitudinal change in clinical and dopamine tran...
Background: Clinical progression of Parkinson\u27s disease (PD) is highly heterogeneous, and its pre...
BACKGROUND: Identifying a meaningful progression metric for Parkinsons disease (PD) that reflects he...
OBJECTIVES: Developing disease modifying therapies for Parkinson's disease (PD) calls for outcome me...
Currently, no treatments available for Parkinson's disease (PD) can slow PD progression. At the earl...
Objective: The aim of this study is to present a predictive model of Parkinson's disease (PD) global...
This thesis examined the factors correlated with rapid and benign progression of disease in a group ...
ObjectiveTo determine clinical and biological variables that predict time to initiation of symptomat...
Background: Both patients and physicians may choose to delay initiation of dopamine replacement ther...
Parkinson's disease is the second most common neurological disease and affects about 1% of persons o...
Background Both patients and physicians may choose to delay initiation of dopamine replacement thera...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...
Parkinson disease (PD) is associated with a clinical course of variable duration, severity, and a co...